Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma has reported that its drug discovery arm, ReceptoPharm, has successfully completed its six-month patient crossover in the Phase IIb/IIIa clinical trial for the treatment of adrenomyeloneuropathy.
Subscribe to our email newsletter
The six-month patient crossover occurred when patients enrolled in the study switched from using a placebo to RPI-78M and those patients currently taking RPI-78M began using a placebo. RPI-78M is ReceptoPharm’s lead drug candidate for the treatment of neurological and autoimmune disorders.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy).
Paul Reid, CEO of ReceptoPharm, said: “This is an important milestone in our clinical development process, as successful completion of this crossover acts as an early indication that our trial is running smoothly.”